Intriguingly, patients with all subtypes of BC or those with ER+ BC receiving treatment but maintaining high levels of AIB1 showed a significantly shorter RFS compared to those patients who had lower levels of AIB1 expression (Figures 7C, D). This evidence concerns the gene NCOA3 and breast cancer.